Therapy Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 1 of 1 entries

Drug Name	Trade Name	Synonyms	Drug Classes	Drug Description
Letrozole	Femara	Letrozol	Aromatase Inhibitor 3	Femara (letrozole) is an aromatase inhibitor, which inhibits estrogen synthesis, and is approved for postmenopausal women with hormone receptor positive breast cancer (FDA.gov).

Showing 1 to 1 of 1 entries

Filter rows:

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 1 of 1 entries

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
PIK3CA mutant	estrogen-receptor positive breast cancer	predicted - sensitive	Letrozole	Phase III	Actionable	In a Phase III trial, estrogen-receptor positive breast cancer patients harboring a PIK3CA mutation demonstrated a greater benefit when treated with Femara (letrozole) compared to Nolvadex (tamoxifen) (PMID: 29902286; NCT00004205).	29902286

Showing 1 to 1 of 1 entries

Filter rows:

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 77 of 77 entries

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT01272037	Phase III	Anastrozole Letrozole Tamoxifen Exemestane	Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer	Active, not recruiting	USA \| IRL \| FRA \| ESP \| CAN	5
NCT01674140	Phase III	Goserelin Anastrozole Letrozole Leuprolide Everolimus Tamoxifen Exemestane	S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer (e3)	Active, not recruiting	USA	1
NCT01797523	Phase II	Letrozole Everolimus Metformin	RAD/Letrozole/Metformin	Active, not recruiting	USA	0
NCT02764541	Phase II	Palbociclib Palbociclib + Tamoxifen Letrozole Tamoxifen	Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)	Active, not recruiting	USA	0
NCT02918084	Phase III	Exemestane Anastrozole Letrozole	CONcurrent vs SEqueNTial Adjuvant Treatments in Early Breast Cancer (GIM10-CONSENT)	Active, not recruiting	ITA	0
NCT02947685	Phase III	Fulvestrant Pertuzumab Letrozole Anastrozole Exemestane Palbociclib Trastuzumab	Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer (PATINA)	Active, not recruiting	USA \| NZL \| ITA \| FRA \| ESP \| DEU \| AUS	1
NCT03820830	Phase III	Anastrozole Exemestane Anastrozole + Palbociclib Letrozole Letrozole + Palbociclib Exemestane + Palbociclib	Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer (POLAR)	Active, not recruiting	ITA \| HUN \| FRA \| ESP \| CHE \| AUT	0
NCT04095364	Phase III	Carboplatin + Letrozole + Paclitaxel Letrozole	Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian or Primary Peritoneal Cancer	Active, not recruiting	USA \| IRL \| CAN	3
NCT04272801	Phase II	Anastrozole Letrozole Tamoxifen Exemestane	Pre-Operative Window of Adjuvant Endocrine Therapy to Inform RT Decisions in Older Women With Early-Stage Breast Cancer (POWER)	Active, not recruiting	USA	0
NCT05101564	Phase II	Amcenestrant Alpelisib Infigratinib Tamoxifen Letrozole Amcenestrant + Letrozole	Umbrella Trial Testing Integrative Subtype Targeted Therapeutics in Estrogen Receptor Positive, HER2-Negative Breast Cancer	Active, not recruiting	USA	0
NCT06001762	Phase II	Tamoxifen Exemestane Abemaciclib Anastrozole Letrozole	TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer	Active, not recruiting	USA	0
NCT01035099	Phase I	Letrozole	RCT of Fixed vs Titrated Letrozole in Breast Cancer Patient Undergoing IVF	Completed	USA	0
NCT01160211	Phase III	Lapatinib + Trastuzumab Letrozole Anastrozole Lapatinib Trastuzumab Exemestane	A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer	Completed	USA \| TUR \| POL \| ITA \| ISR \| HUN \| HRV \| GRC \| GBR \| FRA \| ESP \| DEU \| BRA \| BGR \| BEL \| AUS \| ARG	12
NCT01491737	Phase II	Anastrozole Letrozole Trastuzumab Pertuzumab + Trastuzumab	A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer (PERTAIN)	Completed	USA \| TUR \| ITA \| GBR \| FRA \| ESP \| BRA	1
NCT01669343	Phase I	Letrozole	Aromatase Inhibitor Host Factors Study	Completed	CAN	0
NCT01923168	Phase II	Buparlisib + Letrozole Letrozole Alpelisib + Letrozole	Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women	Completed	USA \| NLD \| LBN \| ITA \| ISR \| ESP \| DEU \| CZE \| CAN \| BRA \| BGR \| BEL \| AUT \| AUS	3
NCT01958021	Phase III	Letrozole + Ribociclib Letrozole	Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2)	Completed	USA \| TUR \| SWE \| NOR \| NLD \| LBN \| ITA \| ISR \| IRL \| HUN \| GBR \| FRA \| FIN \| ESP \| DNK \| DEU \| CZE \| CAN \| BRA \| BEL \| AUT \| AUS \| ARG	6
NCT02010021	Phase I	Letrozole	Presurgical Treatment With Letrozole in Patients With Early-stage Breast Cancer.	Completed	USA	0
NCT02040857	Phase II	Exemestane Palbociclib Tamoxifen Letrozole Anastrozole	A Study of Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer	Completed	USA	0
NCT02095184	Phase 0	Anastrozole Letrozole	GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients	Completed	USA	0
NCT02188745	Phase II	Exemestane Estradiol Anastrozole Letrozole	ER Reactivation Therapy for Breast Cancer (POLLY)	Completed	USA	0
NCT02296801	Phase II	Palbociclib Letrozole	A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer	Completed	USA \| GBR \| CAN	0
NCT02684032	Phase I	Letrozole Fulvestrant Gedatolisib + Palbociclib	A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer	Completed	USA	0
NCT02753686	Phase I	Tamoxifen Exemestane Fulvestrant Letrozole Anastrozole Everolimus + Exemestane	Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy (Treat ER+ight)	Completed	CAN	0
NCT03219476	Phase II	Anastrozole Letrozole Tamoxifen Exemestane	Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer	Completed	USA	0
NCT03306472	Phase II	Letrozole + Megestrol acetate Letrozole	A Pre-operative Window Study of Letrozole Plus PR Agonist (Megestrol Acetate) Versus Letrozole Alone in Post-menopausal Patients With ER-positive Breast Cancer (PIONEER)	Completed	GBR	0
NCT03355157	FDA approved	Exemestane + Palbociclib Tamoxifen Paclitaxel Exemestane Capecitabine Palbociclib + Tamoxifen Epirubicin Vinorelbine Fulvestrant + Palbociclib Fulvestrant Letrozole Letrozole + Palbociclib	A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study). (PADMA)	Completed	DEU	0
NCT03555877	Phase II	Anastrozole Fulvestrant Fulvestrant + Ribociclib Letrozole Exemestane + Ribociclib Letrozole + Ribociclib Anastrozole + Ribociclib Exemestane	Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer (AMICA)	Completed	DEU	0
NCT03747042	Phase I	Letrozole	Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer	Completed	USA	0
NCT03778931	Phase III	Letrozole Exemestane Elacestrant Fulvestrant Anastrozole	Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer (EMERALD)	Completed	USA \| ITA \| ISR \| IRL \| HUN \| GRC \| GBR \| FRA \| ESP \| DNK \| CAN \| BEL \| AUT \| AUS \| ARG	2
NCT03809988	Phase II	Fulvestrant Fulvestrant + Palbociclib Letrozole Letrozole + Palbociclib	PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)	Completed	SVN \| ITA \| GBR \| FRA \| ESP \| DEU	0
NCT03962647	Phase I	Letrozole	A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer	Completed	USA	0
NCT04129216	Phase II	Letrozole Tamoxifen Exemestane	The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer	Completed	USA	0
NCT06223698	Phase III	Letrozole Anastrozole Exemestane Tamoxifen	Optimizing Extended Adjuvant Endocrine Therapy in Patients with Breast Cancer (SWE-Switch)	Not yet recruiting	SWE	0
NCT06348134	Phase II	Tamoxifen Ado-trastuzumab emtansine + Docetaxel + Pertuzumab Letrozole Ado-trastuzumab emtansine Goserelin	Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery	Not yet recruiting	USA	1
NCT03122197	Phase I	Letrozole	Study of Letrozole in Recurrent Gliomas	Recruiting	USA	0
NCT03458221	Phase II	Itraconazole Everolimus Letrozole Bicalutamide	Signal TrAnsduction Pathway Activity Analysis in OVarian cancER (STAPOVER)	Recruiting	NLD	0
NCT03906669	Phase II	Letrozole Tamoxifen	A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer. (WinPro)	Recruiting	AUS	0
NCT04111978	Phase III	Letrozole	MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO) (MATAO)	Recruiting	DEU \| CHE \| AUT	0
NCT04134598	Phase III	Tamoxifen Letrozole Anastrozole Exemestane	ExclUsive endocRine Therapy Or Radiation theraPy for Women Aged >=70 Years Early Stage Breast Cancer (EUROPA)	Recruiting	ITA	0
NCT04568616	Phase II	Letrozole	Phase II Study of Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI) (NAOMI)	Recruiting	USA	0
NCT04614194	Phase II	Letrozole Abemaciclib + Letrozole	Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib	Recruiting	USA	0
NCT04852887	Phase III	Anastrozole Letrozole Tamoxifen Exemestane	De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) (DEBRA)	Recruiting	USA \| CAN	2
NCT04886531	Phase II	Anastrozole + Neratinib + Trastuzumab Letrozole + Neratinib + Trastuzumab Neratinib Anastrozole + Neratinib Letrozole + Neratinib Letrozole Anastrozole Anastrozole + Trastuzumab	Trial of Pre-operative Neratinib and Endocrine Therapy with Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers	Recruiting	USA	0
NCT04961996	Phase III	Exemestane Giredestrant Letrozole Anastrozole	A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)	Recruiting	USA \| TUR \| SWE \| SVN \| SVK \| ROU \| POL \| NLD \| LVA \| ITA \| ISR \| IRL \| HUN \| HRV \| GRC \| GBR \| FRA \| FIN \| ESP \| DEU \| CZE \| CHE \| CAN \| BRA \| BGR \| BEL \| AUT \| AUS \| ARG	25
NCT05150652	Phase II	Exemestane Tamoxifen Letrozole Anastrozole	Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer	Recruiting	USA	0
NCT05183828	FDA approved	Letrozole	Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer	Recruiting	USA	0
NCT05464810	Phase I	Letrozole + Simvastatin Letrozole	Letrozole with and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer	Recruiting	USA	0
NCT05472792	Phase II	Toremifene Exemestane Tamoxifen Letrozole Anastrozole Fulvestrant	Compare Adjuvant Monotherapy With Endocrine or Accelerated Partial Breast Irradiation After Lumpectomy (CAMERAN)	Recruiting	USA	0
NCT05512364	Phase III	Letrozole Anastrozole Exemestane Elacestrant Tamoxifen	Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) (TREAT ctDNA)	Recruiting	ITA \| IRL \| FRA \| DEU \| BEL	0
NCT05514054	Phase III	Letrozole Anastrozole Exemestane Tamoxifen LY3484356	A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer (EMBER-4)	Recruiting	USA \| TUR \| SVK \| ROU \| POL \| NLD \| ITA \| ISR \| IRL \| HUN \| GRC \| GBR \| FRA \| ESP \| DEU \| CZE \| CAN \| BRA \| BEL \| AUT \| AUS \| ARG	9
NCT05601700	Phase III	Carboplatin + Paclitaxel Letrozole	Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial) (LEPRE)	Recruiting	ITA	0
NCT05649956	Phase II	Letrozole	Letrozole in Uterine Leiomyosarcoma	Recruiting	USA	0
NCT05774951	Phase III	Tamoxifen Exemestane Anastrozole Letrozole Camizestrant	A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy (CAMBRIA-1)	Recruiting	USA \| TUR \| ROU \| POL \| NLD \| ITA \| ISR \| HUN \| GRC \| GBR \| FRA \| ESP \| DEU \| CZE \| CAN \| BRA \| BGR \| BEL \| AUT \| AUS \| ARG	18
NCT05952557	Phase III	Tamoxifen Abemaciclib + Tamoxifen Abemaciclib + Exemestane Abemaciclib + Camizestrant Abemaciclib + Letrozole Abemaciclib + Anastrozole Exemestane Anastrozole Letrozole	An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) (CAMBRIA-2)	Recruiting	USA \| TUR \| ROU \| POL \| NZL \| ITA \| ISR \| IRL \| HUN \| HRV \| GRC \| GBR \| FRA \| EST \| ESP \| DEU \| CZE \| CHE \| CAN \| BRA \| BGR \| BEL \| AUT \| AUS \| ARG	19
NCT06016738	Phase III	Fulvestrant Letrozole Anastrozole Palazestrant Exemestane	OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer (OPERA-01)	Recruiting	USA \| ROU \| POL \| NLD \| ITA \| HUN \| GBR \| FRA \| ESP \| DEU \| CZE \| CAN \| BRA \| BGR \| BEL \| AUS \| ARG	8
NCT06044623	Phase III	Exemestane Abemaciclib Palbociclib Ribociclib Letrozole Anastrozole Fulvestrant	Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients (IMPORTANT)	Recruiting	SWE \| NOR \| ITA \| GRC \| FIN \| ESP	0
NCT06072781	Phase III	Paclitaxel Pegylated liposomal doxorubicin Defactinib + RO5126766 Topotecan Anastrozole Letrozole	A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer (RAMP 301)	Recruiting	USA \| NZL \| NLD \| ITA \| IRL \| GBR \| FRA \| ESP \| DEU \| CAN \| BEL \| AUS	1
NCT06179303	Phase II	Tamoxifen Exemestane Abemaciclib Fulvestrant Letrozole Anastrozole	Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer	Recruiting	USA	0
NCT06380751	Phase III	Ribociclib Fulvestrant Camizestrant + Saruparib Anastrozole Camizestrant + Ribociclib Letrozole Camizestrant + Palbociclib Abemaciclib + Camizestrant Exemestane Abemaciclib Palbociclib	Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer (EvoPAR-BR01)	Recruiting	USA \| TUR \| POL \| ITA \| ISR \| HUN \| GBR \| FRA \| ESP \| DEU \| CZE \| CAN \| BRA \| BGR \| AUT \| AUS \| ARG	11
NCT06465368	Phase II	Letrozole Letrozole + PF-07220060	A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause	Recruiting	USA \| SWE \| SVK \| POL \| ITA \| ESP \| BEL \| AUS	2
NCT06492616	Phase III	Exemestane Elacestrant Tamoxifen Letrozole Anastrozole	A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence (ELEGANT)	Recruiting	USA \| ROU \| POL \| NLD \| ITA \| HUN \| GBR \| FRA \| ESP \| DEU \| CZE \| CHE \| CAN \| AUT \| AUS	5
NCT06671912	Phase III	Exemestane Tamoxifen Letrozole Anastrozole	Testing Low Dose Tamoxifen for Invasive Breast Cancer, the (LoTam) Trial (LoTam)	Recruiting	USA	1
NCT00461773	Phase II	Letrozole Bevacizumab	Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer	Terminated	USA	0
NCT00651976	Phase I	Letrozole	Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery	Terminated	USA	0
NCT01296555	Phase I	Fulvestrant Taselisib Letrozole	A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients With Locally Advanced or Metastatic Solid Tumors And in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer	Terminated	USA \| FRA \| ESP \| CAN	0
NCT02115048	Phase II	Afatinib Letrozole	Clinical Study for the Treatment of Breast Cancer the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone	Terminated	USA \| ROU \| ESP	1
NCT02269670	Phase II	Tamoxifen Everolimus Megestrol acetate Letrozole Fulvestrant Anastrozole	Phase II Study of Everolimus Beyond Progression	Terminated	USA	0
NCT04191382	Phase II	Letrozole Amcenestrant	Phase 2 Window Study of SAR439859 Versus Letrozole in ER+, HER2- Pre-operative Post-menopausal Primary Breast Cancer (AMEERA-4)	Terminated	USA \| ITA \| FRA \| ESP \| BEL	4
NCT04289805	FDA approved	Letrozole	Controlled Ovarian Stimulation in Newly Diagnosed Breast Cancer PatiEnts (fAMHOPE) (fAMHOPE)	Terminated	ITA \| FRA \| BEL	0
NCT05447910	Phase II	Letrozole	Analysis of Letrozole in Patients With Operable Hormone Receptor Positive, HER2 Negative Breast Cancer	Terminated	USA	0
NCT02450175	Phase I	Letrozole Everolimus	Etiology of the Platelet-Cancer Metastatic Pathway - A Study of Inflammatory Markers, Platelet Characteristics and Metastatic Surrogates in Cancer Patients and Controls	Unknown status	USA	0
NCT02689921	Phase II	Anastrozole Letrozole Leuprolide Pertuzumab + Trastuzumab Exemestane	NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer (NEOADAPT)	Unknown status	USA	0
NCT02619669	Phase I	Sapanisertib Letrozole	Neoadjuvant Run-In Study With TAK-228 (MLN0128) Followed by Letrozole/TAK-228 (MLN0128) in Women With High-Risk ER+/HER2- Breast Cancer	Withdrawn	USA	0
NCT03238703	FDA approved	Tamoxifen Exemestane Toremifene Anastrozole Letrozole	Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer	Withdrawn	USA	0
NCT05238831	Phase II	Vemurafenib Vinorelbine Palbociclib Irinotecan Alpelisib Capecitabine Atezolizumab Paclitaxel Entrectinib Cobimetinib Nab-paclitaxel Fulvestrant Carboplatin Olaparib Pertuzumab/trastuzumab/hyaluronidase-zzxf Niraparib Vismodegib Alectinib Letrozole Ado-trastuzumab emtansine Bevacizumab Eribulin Anastrozole	SMMART Adaptive Clinical Treatment (ACT) Trial	Withdrawn		0
NCT05712941	Phase III	G1T38 + Letrozole Letrozole	Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients With Advanced/Metastatic or Recurrent, Grade 1 or Grade 2 Endometrial Cancer	Withdrawn		0

Showing 1 to 77 of 77 entries

Filter rows:

Therapy Detail

Contact

Filtering

Sorting

Filtering

Sorting

Filtering

Sorting

Additional content available in CKB BOOST